Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 2, 2003 - Issue 6
Submit an article Journal homepage
213
Views
82
CrossRef citations to date
0
Altmetric
Review

Hepatotoxicity of thiazolidinediones

William L Isley Mayo Clinic, W18A, 200 First Street SW, Rochester, MN 55905, USA. [email protected]
Pages 581-586 | Published online: 03 Mar 2005

Bibliography

  • FRANCIS GA, FAYARD E, PICARD F, AUWERX J: Nuclear receptors and the control of metabolism. Annu. Rev. Physiol (2003) 65:261–311.
  • NO AUTHORS LISTED: From the Food and Drug Administration. JAMA (2000) 283:2228.
  • WISE J: Diabetes drug withdrawn after reportsof hepatic events. Br. Med. J. (1997) 315:1564.
  • O'KEEFE JH Jr, MILES JM, HARRIS WH, MOE RM, MCCALLISTER BD: Improving the adverse cardiovascular prognosis of Type 2 diabetes. Mayo Clin. Proc. (1999) 74:171–180.
  • BERKOWITZ K, PETERS R, KJOS SL et al.: Effect of troglitazone on insulin sensitivity and pancreatic I3-cell function in women at high risk for NIDDM. Diabetes (1996) 45:1572–1579.
  • SCHWARTZ S, RASKIN P, FONSECA V, GRAVELINE JF: Effect of troglitazone in insulin-treated patients with Type II diabetes mellitus: Troglitazone Exogenous Insulin Study Group. N Engl. J. Med. (1998) 338:861–866.
  • BUCHANAN TA, XIANG AH, PETERS RK et al: Preservation of pancreatic 13-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes (2002) 51:2796–2803.
  • NEUSCHWANDER-TETRI BA, ISLEY WI, OKI JC et al.: Troglitazone-induced hepatic failure leading to liver transplantation. Ann. Intern. Med. (1998) 129:38–41.
  • GITLIN N, JULIE NL, SPURR CL, LIM KIN, JUARBE HM: Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann. Intern. Med. (1998) 129:36–38.
  • VELLA A, DE GROEN PC, DINNEEN SF: Fatal hepatotoxicity associated with troglitazone. Ann. Intern. Med. (1998) 129:1080. Letter.
  • HERRINE SK, CHOUDHARY C: Severe hepatotoxicity associated with troglitazone. Ann. Intern. Med. (1999) 130:163-164. Letter.
  • SHIBUYA A, WATANABE M, FUJITA Y et al: An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care (1998) 21:2140–2143.
  • IWASE M, YAMAGUCHI M, YOSHINARI M et al.: A Japanese case of liver dysfunction after 19 months of troglitazone treatment. Diabetes Care (1999) 22:1382–1384.
  • PRENDERGAST KA, BERG CL,WISNIEWSKI R: Troglitazone-associated hepatotoxicity treated successfully with steroids. Ann. Intern. Med. (2000) 133:751.
  • KOHLROSER J, MATHIA J, REICHHELD H, BANNER BF, BONKOVSKY HL: Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am. J Gastroenterol. (2000) 95:272–276.
  • FUKANO M, AMANO S, SATO J et aL:Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination. Hum. Pathol. (2000) 31:250–253.
  • BOOTH AM, CALDWELL SH, IEZZONI JC: Troglitazone associated hepatic failure. Am. J. Gastroenterol. (2000) 95:557–558.
  • MALIK AH, PRASAD P, SABOORIAN MH, THIELE DL, MALET PF: Hepatic injury due to troglitazone. Dig. Dis. Sci. (2000) 45:210–214.
  • MURPHY EJ, DAVERN TJ, SHAKIL AO et al.: Troglitazone induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig. Dis. Sci. (2000) 45:549–553.
  • JAGANNATH S, RAI R: Rapid-onset subfulminant liver failure associated with troglitazone. Ann. Intern. Med. (2000) 18:677.
  • SCHIANO T, DOLEHIDE K, HART J, BAKER AL: Severe but reversible hepatitis induced by troglitazone. Dig. Dis. Sci. (2000) 45:1039–1042.
  • BELL DS, OVALLE F: Late-onset troglitazone-induced hepatic dysfunction. Diabetes Care (2000) 23:128–129.
  • ISLEY wL, OKI JC: Hepatotoxicity of thiazolidinediones. Diabetes Obes. Metab. (2001) 3:389–392.
  • ••Detailed description of the history of troglitazone-induced hepatotoxicity.
  • SCHEEN AJ: Hepatotoxicity with thiazolidinediones. Drug Saf (2001) 24:873–888.
  • GRAHAM D: Presentation at Endocrinologic and Metabolic Drugs Advisory Committee, United States Food and Drug Administration. Bethesda, USA. 26 March (1999).
  • PRESCRIBING INFORMATION FOR AVANDIA: SmithKline Beecham. April 2000.
  • PRESCRIBING INFORMATION FOR ACTOS: Takeda Pharmaceuticals America, Inc./Eli Lilly. November 1999.
  • WATKINS PB, WHITCOMB RW: Hepatic dysfunction associated with troglitazone. N. Engl. J Med. (1998) 338:916-917. Letter.
  • PRESCRIBING INFORMATION FOR REZULIN: Parke-Davis. March 1997.
  • PRESCRIBING INFORMATION FOR REZULIN: Parke-Davis. November 1997.
  • PRESCRIBING INFORMATION FOR REZULIN: Parke-Davis. July 1998.
  • FORMAN LM, SIMMONS DA, DIAMOND RH: Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med. (2000) 132:118–121.
  • •Case report of rosiglitazone-related hepatic injury. Causal relationship to the drug is unclear, as discussed in [35].
  • AL-SALMAN J, ARJOMAND H, KEMP DG, MITTAL M: Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann. Intern. Med. (2000) 132:121–124.
  • •Case report of rosiglitazone-related hepatic injury. Causal relationship to the drug is unclear, as discussed in [35].
  • FREID J, EVERITT D, BOSCIA J: Rosiglitazone and liver failure. Ann. Intern. Med. (2000) 132:164. Letter.
  • ISLEY WL, OKI JC: Rosiglitazone and liver failure. Ann. Intern. Med. (2000) 133:393. Letter.
  • RAVINUTHALA RS, NORI U: Rosiglitazone toxicity. Ann. Intern. Med. (2000) 133:658. Letter.
  • BONKOVSKY HL, ASAR R, BIRD S, SZABO G, BANNER B: Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig. Dis. Sci. (2002) 47:1632–1637.
  • LEBOVITZ HE, KREIDER M, FREED MI: Evaluation of liver function in Type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care (2002) 25:815–821.
  • ••Review of liver toxicity data from allclinical trials of rosiglitazone to that date, showing no sign of severe liver injury.
  • MAEDA K: Hepatocellular injury in a patient receiving pioglitazone. Ann. Intern. Med. (2001) 135:306. Letter.
  • •Case report of pioglitazone-related hepatic injury.
  • MAY LD, LEFKOWITCH JH, KRAM MT, RUBIN DE: Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann. Intern. Med. (2002) 136:449–452.
  • •Case report of pioglitazone-related hepatic injury.
  • PINTO AG, CUMMINGS OW, CHALASANI N: Severe but reversible cholestatic liver injury after pioglitazone therapy. Ann. Intern. Med. (2002) 137:857. Letter.
  • •Case report of pioglitazone-related hepatic injury.
  • LEE WM: Drug-induced hepatotoxicity. N Engl. J Med. (2003) 349:474–485.
  • YAMAMOTO Y, NAKAJIMA M, YAMAZAKI H, YOKOI T: Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Lifi Sci. (2001) 70:471–482.
  • LLOYD S, HAYDEN MJ, SAKAI Yet al.: Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chem. Biol. Interact. (2002) 142:57–71.
  • ••In vitro study of hepatocellular toxicity ofrosiglitazone and troglitazone, showing innate toxicity of both native molecules. However, troglitazone showed far more toxicity than rosiglitazone.
  • EVERETT L, GALLI A, CRABB D: The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver (2000) 20:191–199.
  • JIA DM, TABARU A, AKIYAMA T, ABE S, OTSUKI M: Troglitazone prevents fatty changes of the liver in obese diabetic rats. J. Gastroenterol Hepatol (2000) 15:1183–1191.
  • CALD WELL SH, HESPENHEIDE EE, REDICK JA et aL: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol (2001) 96:519–525.
  • NEUSCHWANDER-TETRI BA, BRUNT EM, WEHMEIER KR et a/.: Interim results of a pilot study demonstrating the early effects of the PPAR-y ligand rosiglitazone on insulin sensitivity, arninotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. Hepatol (2003) 38:434–440.
  • •Pilot study of rosglitazone therapy for NASH.
  • FREEDMAN R, UNXTAIFO G, LUTCHMAN G et al.: Changes in insulin sensitivity and improvements in liver histology in patients with nonalcoholic steatohepatitis (NASH) treated with pioglitazone (PIO). Diabetes (2003) 52\(Suppl. 1):A76. Abstract 324-0R.
  • BOELSTERLI UA, BEDOUCHA M: Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARy) expression in the liver: insights from models of obesity and Type 2 diabetes. Biochenz. Pharmacol (2002) 63:1–10.
  • ISLEY WL: Glitazones: good for glycemia.Good for the liver? Diabetes Technol Ther. (2003) 5:43–44.
  • MOFRAD P, CONTOS MJ, HAQUE M et al.: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 37:1286–1292.

Website

  • http://www.fda.gov/ohrms/dockets/ac/00/ slides/3615s1a/s1d001.htm LUMPKIN MJ: Presentation at Endocrinologic and Metabolic Drugs Advisory Committee, United States Food and Drug Administration. Bethesda, USA. 19 May (2000). Accessed 6/18/2003.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.